About: http://data.cimple.eu/news-article/c14b99f9cfe611cac8daf7f7551b096cfbf0b2758ba29365b9ab561f

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/c14b99f9cfe611cac8daf7f7551b096cfbf0b2758ba29365b9ab561f Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Prime Minister Justin Trudeau on Tuesday announced an investment of nearly Can$200 million (US$166 million) in an Ontario facility that will be capable of producing millions of mRNA vaccines like the shots being used to fight the coronavirus pandemic. The investment in Resilience Biotechnologies, the Canadian subsidiary of US firm National Resilience, should help Canada become less reliant on foreign-made vaccines, as it has been during the current Covid-19 crisis. The expansion of the Resilience Biotech plant in Mississauga is "essential to be prepared to face any future health crisis," Trudeau told a news conference. Canada currently has no domestic vaccine production, and so has depended on imports of Pfizer-BioNTech, Moderna and other jabs to inoculate its 38 million people against coronavirus. Industry Minister François-Philippe Champagne said the government investment in Resilience -- about half of the total project costs -- will support the development of "medical countermeasures to Covid-19 and strengthen Canada's emergency preparedness for future pandemics." Once the expansion of the Resilience factory is completed in 2024, the plant will be able to manufacture between 112 and 640 million vaccine doses each year. It will also create 500 new jobs and anchor Canada's plans to boost its biomanufacturing and life sciences sector. To this end, Ottawa earmarked in its budget unveiled last month a total of Can$2.2 billion. The Canadian government has already recently committed significant funding in support of similar projects from other groups such as French pharmaceutical giant Sanofi and Canadian biotech firm Medicago. Medicago earlier reported positive interim results from mid-stage trials of its plant-derived Covid-19 vaccine candidate. Sanofi's expanded Toronto plant will primarily produce flu shots -- enough for all Canadians -- but can also be retooled to produce coronavirus vaccines. jl/amc/sst
schema:headline	Dependent on foreign jabs, Canada invests in vaccine production
schema:mentions	Mississauga Reliant Motors Biology Pharmaceutical industry French language Toronto Ottawa Prime Minister of Canada Justin Trudeau Influenza Messenger RNA Canada Pandemic Vaccine Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 Biomedical Advanced Research and Development Authority Biomanufacturing Government of Ontario Medicago François-Philippe Champagne American Motors Corporation Sanofi Singapore Standard Time
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-05-18 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	93 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software